2MW 4691
Alternative Names: 2MW-4691Latest Information Update: 15 Jun 2024
At a glance
- Originator Mabwell (Shanghai) Bioscience
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CCR8 receptor antagonists; CTLA 4 antigen expression inhibitors; Regulatory T-lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 05 Apr 2024 Pharmacodynamics, pharmacokinetics and adverse events data from the preclinical studies in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 18 Mar 2024 Preclinical trials in Cancer in China before March 2024 (Parenteral)
- 12 Mar 2024 Pharmacodynamics and adverse events data from the preclinical studies in Cancer released by Mabwell (Shanghai) Bioscience